Head to Head Contrast: BioNano Genomics (BNGO) & Bio-Rad Laboratories (BIO)

BioNano Genomics (NASDAQ:BNGO) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.


This table compares BioNano Genomics and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNano Genomics N/A N/A N/A
Bio-Rad Laboratories 55.13% 3.72% 2.67%

Valuation and Earnings

This table compares BioNano Genomics and Bio-Rad Laboratories’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNano Genomics $9.50 million 7.23 -$23.36 million N/A N/A
Bio-Rad Laboratories $2.16 billion 3.82 $122.24 million $4.10 67.42

Bio-Rad Laboratories has higher revenue and earnings than BioNano Genomics.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioNano Genomics and Bio-Rad Laboratories, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNano Genomics 0 0 2 0 3.00
Bio-Rad Laboratories 0 3 4 0 2.57

BioNano Genomics presently has a consensus target price of $12.00, suggesting a potential upside of 75.18%. Bio-Rad Laboratories has a consensus target price of $339.17, suggesting a potential upside of 22.70%. Given BioNano Genomics’ stronger consensus rating and higher probable upside, research analysts clearly believe BioNano Genomics is more favorable than Bio-Rad Laboratories.

Insider & Institutional Ownership

0.5% of BioNano Genomics shares are held by institutional investors. Comparatively, 63.8% of Bio-Rad Laboratories shares are held by institutional investors. 28.0% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Bio-Rad Laboratories beats BioNano Genomics on 8 of the 11 factors compared between the two stocks.

BioNano Genomics Company Profile

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply